Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker study

BACKGROUND: Single-agent immunotherapy is currently the recommended second-line therapy for patients with advanced non–small cell lung cancer (NSCLC) without targetable mutations; however, the objective response rate (ORR) remains low. This phase II study evaluated the efficacy of the combination th...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yongchang, Song, Lianxi, Zeng, Liang, Xiong, Yi, Liu, Li, Zhou, Chunhua, Yang, Haiyan, Wang, Zhan, Xia, Qing, Jiang, Wenjuan, Xu, Qinqin, Yang, Nong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9446552/
https://www.ncbi.nlm.nih.gov/pubmed/36064386
http://dx.doi.org/10.1186/s12885-022-10045-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9446552/
https://www.ncbi.nlm.nih.gov/pubmed/36064386
http://dx.doi.org/10.1186/s12885-022-10045-0

Ejemplares similares